Cannabis Extracts Outperformed Individual Cannabinoids in Reducing Gut Inflammation in Lab Cells

Cannabis extracts standardized for CBD and CBG content inhibited pro-inflammatory chemokines (CXCL-9, CXCL-10, CCL-20) in inflammation-stimulated intestinal cells. Critically, the whole extracts showed greater effect than individual cannabinoids at equivalent concentrations in a co-culture inflammation model, partially recovering epithelial barrier integrity measured by TEER and ZO-1 expression.

Researchers tested two cannabis extracts (different extraction solvents, same CBD/CBG standardization) and individual cannabinoids on CaCo-2 intestinal cells stimulated with IL-1beta and IFN-gamma. The extracts underwent simulated digestion before testing. A CaCo-2/THP-1 co-culture model assessed barrier function. NF-kB activity was measured to determine mechanism.

IBD patients increasingly report using cannabis, but clinical trial evidence is limited. This study supports the "entourage effect" hypothesis for gut inflammation, showing that the complex mix of compounds in cannabis extracts may be more effective than isolated CBD or CBG, and identifies specific anti-inflammatory mechanisms.

The observation that extraction method influences which inflammatory pathways are targeted (Extract A vs. B had different effects despite the same CBD/CBG content) highlights the importance of standardization in cannabis-based medicine. Different extraction methods may yield products with different therapeutic profiles.

In vitro cell model does not replicate the full complexity of IBD in living patients. Simulated digestion approximates but does not perfectly match human gastrointestinal processing. The specific extracts tested may not represent commercially available products.